Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Maze Therapeutics
Maze Therapeutics
Metsera, Maze secure combined $415 million in IPOs
BioPharma Dive
Fri, 01/31/25 - 11:05 am
Metsera
Maze Therapeutics
IPOs
biotech
Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing
Fierce Biotech
Tue, 01/28/25 - 10:41 am
Maze Therapeutics
IPOs
kidney disease
clinical trials
Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials
Fierce Biotech
Tue, 01/7/25 - 07:04 pm
Maze Therapeutics
IPOs
kidney disease
Maze Therapeutics Raises $115M in Series D Financing
FinSMEs
Tue, 12/3/24 - 11:31 am
Maze Therapeutics
funding
Maze Therapeutics reports positive data from Phase I AKD treatment trial
Clinical Trials Arena
Mon, 10/28/24 - 11:17 am
Maze Therapeutics
MZE829
kidney disease
clinical trials
Maze lands new partner for Pompe drug, after Sanofi pact came apart
BioPharma Dive
Fri, 05/10/24 - 11:29 am
Maze Therapeutics
Pompe disease
Shionogi
FTC
Sanofi
MZE001
Failed Illumina and Sanofi Deals Shine Light on FTC Antitrust Crackdown
BioSpace
Wed, 12/20/23 - 06:41 pm
Illumina
Grail
Sanofi
Maze Therapeutics
FTC
M&A
antitrust
FTC, in unusual move, leads Sanofi to terminate a drug research deal
BioPharma Dive
Tue, 12/12/23 - 10:43 pm
FTC
Sanofi
R&D
Maze Therapeutics
Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge
BioSpace
Tue, 12/12/23 - 09:57 am
Ssanofi
Maze Therapeutics
Pompe disease
FTC
legal
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
BioPharma Dive
Mon, 05/1/23 - 10:10 am
Maze Therapeutics
Pompe disease
Sanofi
MZE001
CEO Shakeups at BIO, Passage Bio and Palisade Bio
BioSpace
Fri, 10/14/22 - 10:23 am
BIO
Passage Bio
Palisade Bio
Maze Therapeutics
Cerecin
Pharma CEOs
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Fierce Biotech
Mon, 01/10/22 - 11:45 am
Maze Therapeutics
funding
MZE001
Pompe disease
Maze Therapeutics debuts with $191M to go after genetic modifiers
Fierce Biotech
Fri, 03/1/19 - 09:27 am
Maze Therapeutics
genetic modifiers